Physician profile
Douglas Peterson
NPI 1831185040
$479.50
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.68 · 2020: $261 · 2021: $87.79 · 2022: $66.47.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $152.23 | 2019-2022 | |
| Janssen Biotech, INC. | $137.74 | 2019-2020 | |
| Gilead Sciences, INC. | $42.76 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.08 | 2020 | |
| Pfizer INC. | $32.96 | 2021 | |
| Alexion Pharmaceuticals, INC. | $22.30 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.61 | 2019 | |
| Intercept Pharmaceuticals, INC. | $16.13 | 2020 | |
| Nestle Healthcare Nutrition INC. | $11.95 | 2021 | |
| Celgene Corporation | $11.74 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.